Ontology highlight
ABSTRACT:
PROVIDER: EGAC00001000321 | EGA |
REPOSITORIES: EGA
Eleveld Thomas F TF Oldridge Derek A DA Bernard Virginie V Koster Jan J Colmet Daage Léo L Diskin Sharon J SJ Schild Linda L Bentahar Nadia Bessoltane NB Bellini Angela A Chicard Mathieu M Lapouble Eve E Combaret Valérie V Legoix-Né Patricia P Michon Jean J Pugh Trevor J TJ Hart Lori S LS Rader JulieAnn J Attiyeh Edward F EF Wei Jun S JS Zhang Shile S Naranjo Arlene A Gastier-Foster Julie M JM Hogarty Michael D MD Asgharzadeh Shahab S Smith Malcolm A MA Guidry Auvil Jaime M JM Watkins Thomas B K TB Zwijnenburg Danny A DA Ebus Marli E ME van Sluis Peter P Hakkert Anne A van Wezel Esther E van der Schoot C Ellen CE Westerhout Ellen M EM Schulte Johannes H JH Tytgat Godelieve A GA Dolman M Emmy M ME Janoueix-Lerosey Isabelle I Gerhard Daniela S DS Caron Huib N HN Delattre Olivier O Khan Javed J Versteeg Rogier R Schleiermacher Gudrun G Molenaar Jan J JJ Maris John M JM
Nature genetics 20150629 8
The majority of patients with neuroblastoma have tumors that initially respond to chemotherapy, but a large proportion will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole-genome sequencing of 23 paired diagnostic and relapse neuroblastomas showed clonal evolution from the diagnostic tumor, with a median of 29 somatic mutations unique to the relapse sample. Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the ...[more]